Research output per year
Research output per year
Fingerprint
Dive into the research topics where Barbara Zellinger is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
-
Durable Response to Glofitamab in HIV-Positive Refractory Burkitt Lymphoma: Case Report and Discussion
Elisa, B., Theresa, M. (Co-author), Dominik, K. (Co-author), Barbara, Z. (Co-author), Daniel, N. (Co-author), Arno, B., Alexander, E. (Co-author) & Thomas, M. (Last author), Feb 2026, In: EJHAEM. 7, 1, 8 p., e70243.Research output: Contribution to journal › Original Article › peer-review
Open Access -
1870 Delta changes in 18-FDG PET/CT parameters can prognosticate clinical outcomes in recurrent NSCLC patients who have undergone reirradiation
Grambozov, B. (First author), Zamani-Siahkali, N. (Co-author), Stana, M. (Co-author), Beheshti, M. (Co-author), Ruznic, E. (Co-author), Iskakova, Z. (Co-author), Karner, J. (Co-author), Zellinger, B. (Co-author), Gerum, S. (Co-author), Röder, F. (Co-author), Pirich, C. (Co-author) & Zehentmayr, F. (Last author), 2025, In: RADIOTHERAPY AND ONCOLOGY. 2025, 206:S1336-S1337Research output: Contribution to journal › Abstract (Journal) › peer-review
Open Access -
203P: Immunotherapy improves clinical outcome in KRAS mutated patients with unresectable NSCLC stage III: A subcohort analysis of the Austrian radio-oncological lung cancer study association regristry (ALLSTAR)
Zehentmayr, F. (First author), Klebermass, M. (Co-author), Zellinger, B. (Co-author), Langer, B. (Co-author), Grambozov, B. (Co-author), Purevdorj, A. (Co-author), Karner, J. (Co-author), Gruber, G. (Co-author), Stana, M. (Co-author), Minasch, D., Kirchhammer, K. (Co-author), Steffal, C. (Co-author), Stranzl, H. (Co-author), Moosbrugger, R. (Co-author), Feurstein, P. (Co-author), Dieckmann, K. (Co-author) & Ruznic, E. (Co-author), 2025, In: JOURNAL OF THORACIC ONCOLOGY.Research output: Contribution to journal › Abstract (Journal) › peer-review
Open Access -
Delta Changes in [18F]FDG PET/CT Parameters Can Prognosticate Clinical Outcomes in Recurrent NSCLC Patients Who Have Undergone Reirradiation–Chemoimmunotherapy
Grambozov, B. (First author), Zamani-Siahkali, N., Stana, M. (Co-author), Beheshti, M. (Co-author), Ruznic, E. (Co-author), Iskakova, Z. (Co-author), Karner, J. (Co-author), Zellinger, B. (Co-author), Gerum, S. (Co-author), Roeder, F. (Co-author), Pirich, C. (Co-author) & Zehentmayr, F. (Last author), 31 Jul 2025, In: BIOMEDICINES. 13, 8, 15 p., 1866.Research output: Contribution to journal › Original Article › peer-review
Open Access -
Durvalumab Is Associated with Prolonged Progression-Free Survival, While Concomitant Chemoradiotherapy May Improve Both Locoregional and Local Control in Elderly Patients with Unresectable NSCLC Stage III: Subanalysis of the Austrian Radio-Oncological Lung Cancer Study Association Registry (ALLSTAR)
Zehentmayr, F. (First author), Karner, J. (First author), Stana, M. (Co-author), Ruznic, E. (Co-author), Zellinger, B. (Co-author), Klebermass, M., Purevdorj, A., Gruber, G., Minasch, D., Heilmann, M., Moosbrugger, R. (Co-author), Roeder, F. (Co-author) & Grambozov, B. (Last author), 5 Dec 2025, In: Medical Sciences. 13, 4, 15 p., 305.Research output: Contribution to journal › Original Article › peer-review
Open Access
Projects
- 2 Finished
-
Mutational analysis of BRCAness genes in triple-negative breast cancer by next-generation sequencing
Zellinger, B. (PI)
1/12/18 → 1/12/19
Project: Research
-
NR2F1-ERalpha induced hsa-miR-375 promotes local relapse in breast cancer by targeting RASD1
Sedlmayer, F. (Further contributor), Zehentmayr, F. (PI), Zellinger, B. (Further contributor) & Kronberger, C. (Further contributor)
1/02/18 → 1/02/19
Project: Research